Deciphera Pharmaceuticals (DCPH) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results
May 4, 2021 4:22 PM EDT- First Quarter 2021 QINLOCK® Net Product Revenue of $20.0 Million; QINLOCK Approved in China and Hong Kong for Fourth-line GIST -
- Top-line Results from INTRIGUE Phase 3 Study of QINLOCK in Patients with Second-line GIST Expected in the Fourth Quarter of 2021; Plans to Initiate a Phase 1b/2 Study of QINLOCK in Combination with Binimetinib in Patients with Post-Imatinib GIST -
- Updated Data from Phase 1b/2 Study of Rebastinib in Combination with Paclitaxel in Patients with Endometrial Cancer to be Presented at ASCO -
-... More
